Bupivacaine Epiphora Trial

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

WITHDRAWN

Clinical Phase

PHASE2

Study Classification

INTERVENTIONAL

Study Start Date

2015-04-30

Study Completion Date

2022-08-23

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The objective of this study is to investigate quantitative improvement in excessive tearing after administration of Bupivacaine, a local anesthetic, into the affected eyelids.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Pain Reduction With Topical Bromfenac Versus Artificial Tear After Intravitreal Injection.

NCT06130384

Pain Intravitreal Injection Pain, Acute

COMPLETED PHASE4

Subconjunctival Bupivacaine in Strabismus Surgery

NCT04782960

Anesthesia, Local

UNKNOWN NA

Subconjunctival Injection of Local Anesthetic in Anterior Blepharoptosis Repair

NCT02959697

Blepharoptosis Ptosis

UNKNOWN NA

Subconjunctival Atropine and Intracameral Epinephrine for Pupil Dilation in Phacoemulsification

NCT03638726

Cataract Mydriasis Adverse Drug Event

UNKNOWN PHASE4

Comparing Post-intravitreal Injection Pain Scores Using Loteprednol, Bromfenac Sodium, and Artificial Tears Over a 24-hour Period

NCT07090044

Vein Occlusion Macular Degeneration Choroidal Neovascularization Macular Edema +1 more

COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Epiphora Ptosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

0.75% bupivacaine

Group Type EXPERIMENTAL

0.75% bupivacaine

Intervention Type DRUG

topical anesthetic

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

0.75% bupivacaine

topical anesthetic

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Patients age 18 and above, patients with unilateral or bilateral excessive tearing.

Exclusion Criteria

Pregnant females, vulnerable populations, patients with severe hepatic disease, or patients using monoamine oxidase inhibitors or tricyclic antidepressants, which are contraindicated with bupivacaine and norepinephrine combinations.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes